Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
[en] BACKGROUND: While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn's disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable efficacy during maintenance treatment, comparative data specific to subcutaneous (SC) IFX (i.e., CT-P13 SC) versus VDZ are limited. AIM: Pooled analysis of randomised studies to compare efficacy and safety with IFX SC and VDZ in moderate-to-severe inflammatory bowel disease. METHODS: Parallel-group, randomised studies evaluating IFX SC and VDZ in patients with moderate-to-severe CD or UC were identified. Eligible studies reported ≥ 1 prespecified outcome of interest at Week 6 (reflecting treatment during the induction phase) and/or at 1 year (Weeks 50-54; reflecting treatment during the maintenance phase). Prespecified efficacy and safety outcomes considered in this pooled analysis included the proportions of patients achieving disease-specific clinical responses, clinical remission, or discontinuing due to lack of efficacy, and the proportions of patients experiencing adverse events (AEs), serious AEs, infections, serious infections, or discontinuing due to AEs. Data from multiple studies or study arms were extracted and pooled using a random-effect model; comparative analyses were performed separately for patients with CD and UC. RESULTS: We identified three eligible CD trials and four eligible UC trials that assigned over 1200 participants per disease cohort to either IFX SC or VDZ. In patients with CD, intravenous induction therapy with IFX demonstrated better efficacy (non-overlapping 95% confidence intervals [CIs]) compared with VDZ; during the maintenance phase, IFX SC showed numerically better efficacy (overlapping 95% CIs) than VDZ. A lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In patients with UC, efficacy profiles were similar with IFX SC and VDZ during the induction and maintenance phases, and a lower proportion of IFX SC-treated patients discontinued therapy due to lack of efficacy over 1 year. In both cohorts, safety profiles for IFX SC and VDZ were generally comparable during 1 year. CONCLUSION: IFX SC demonstrated better efficacy than VDZ in patients with CD, and similar efficacy to VDZ in patients with UC; 1-year safety was comparable with IFX SC and VDZ.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Peyrin-Biroulet, Laurent; Department of Gastroenterology, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.
Arkkila, Perttu; Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.
Armuzzi, Alessandro; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
Danese, Silvio; Gastroenterology and Endoscopy, University Vita-Salute San Raffaele, Milan, Italy.
Ferrante, Marc; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Jordi, Guardiola; Department of Digestive Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Jahnsen, Jørgen; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Lukáš, Milan; Clinical and Research Center for Inflammatory Bowel Diseases, ISCARE Clinical Centre, Prague, Czech Republic.
Reinisch, Walter; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Roblin, Xavier; Department of Gastroenterology and Hepatology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Smith, Philip J; Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Kwon, Taek; Celltrion, Incheon, Republic of Korea.
Kim, Jeeyoung; Celltrion, Incheon, Republic of Korea.
Yoon, Sangwook; Celltrion, Incheon, Republic of Korea.
Kim, Dong-Hyeon; Celltrion, Incheon, Republic of Korea.
Atreya, Raja; Medical Department 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany. raja.atreya@uk-erlangen.de.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
R. Ungaro S. Mehandru P.B. Allen L. Peyrin-Biroulet J.F. Colombel Ulcerative colitis Lancet 2017 389 10080 1756 1770 10.1016/S0140-6736(16)32126-2 27914657
C.A. Lamb N.A. Kennedy T. Raine P.A. Hendy P.J. Smith J.K. Limdi B. Hayee M.C.E. Lomer G.C. Parkes C. Selinger et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults Gut 2019 68 Suppl 3 s1 s106 10.1136/gutjnl-2019-318484 31562236
M. Fumery S. Singh P.S. Dulai C. Gower-Rousseau L. Peyrin-Biroulet W.J. Sandborn Natural history of adult ulcerative colitis in population-based cohorts: a systematic review Clin Gastroenterol Hepatol 2018 16 3 343 356.e3 10.1016/j.cgh.2017.06.016 28625817
J. Burisch G. Kiudelis L. Kupcinskas H.A.L. Kievit K.W. Andersen V. Andersen R. Salupere N. Pedersen J. Kjeldsen R. D'Incà et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study Gut 2019 68 3 423 433 10.1136/gutjnl-2017-315568 29363534
J. Torres S. Bonovas G. Doherty T. Kucharzik J.P. Gisbert T. Raine M. Adamina A. Armuzzi O. Bachmann P. Bager et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment J Crohns Colitis 2020 14 1 4 22 10.1093/ecco-jcc/jjz180 31711158
T. Raine S. Bonovas J. Burisch T. Kucharzik M. Adamina V. Annese O. Bachmann D. Bettenworth M. Chaparro W. Czuber-Dochan et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment J Crohns Colitis 2022 16 1 2 17 10.1093/ecco-jcc/jjab178 34635919
S. Schreiber S. Ben-Horin R. Alten R. Westhovens L. Peyrin-Biroulet S. Danese T. Hibi K. Takeuchi F. Magro Y. An et al. Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era Adv Ther 2022 39 6 2342 2364 1:CAS:528:DC%2BB38Xlt1Krug%3D%3D 10.1007/s12325-021-01990-6 34988877 8731678
L. Peyrin-Biroulet P. Arkkila A. Armuzzi S. Danese J. Guardiola J. Jahnsen C. Lees E. Louis M. Lukas W. Reinisch et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis BMC Gastroenterol 2022 22 1 291 1:CAS:528:DC%2BB38XitFent77P 10.1186/s12876-022-02347-1 35676620 9178865
C. Allamneni K. Venkata H. Yun F. Xie L. DeLoach T.A. Malik Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a tertiary inflammatory bowel disease center Gastroenterology Res 2018 11 1 41 45 1:CAS:528:DC%2BC1MXhtlOitrnI 10.14740/gr934w 29511405 5827901
S. Singh M.H. Murad M. Fumery R. Sedano V. Jairath R. Panaccione W.J. Sandborn C. Ma Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis Lancet Gastroenterol Hepatol 2021 6 12 1002 1014 10.1016/S2468-1253(21)00312-5 34688373 8933137
Remsima: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf. Accessed 4 Dec 2023.
Remsima: extension of indication variation assessment report. https://www.ema.europa.eu/en/documents/variation-report/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed 4 Dec 2023.
Remsima: procedural steps taken and scientific information after the authorisation. https://www.ema.europa.eu/en/documents/procedural-steps-after/remsima-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf. Accessed 4 Dec 2023.
A. Heald S. Bramham-Jones M. Davies Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: a brief UK stakeholder survey Int J Clin Pract 2021 75 9 e14341 1:CAS:528:DC%2BB3MXhs1CmtbnI 10.1111/ijcp.14341 33963659
F. D'Amico V. Solitano D. Aletaha A. Hart F. Magro C. Selmi S.C. Ng S. Al Awadhi E. Choy H. Schulze-Koops et al. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus Autoimmun Rev 2021 20 7 102849 10.1016/j.autrev.2021.102849 33974946
R. Westhovens P. Wiland M. Zawadzki D. Ivanova A.B. Kasay E.C. El-Khouri E. Balazs S. Shevchuk L. Eliseeva M. Stanislavchuk et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial Rheumatology (Oxford) 2021 60 5 2277 2287 1:CAS:528:DC%2BB3MXhslSgt7jJ 10.1093/rheumatology/keaa580 33230526
W. Reinisch B.I. Jang V. Borzan A. Lahat A. Pukitis M. Osipenko Y. Mostovoy S. Schreiber S. Ben-Horin S.J. Lee et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn’s disease J Crohns Colitis 2019 13 S066 S067 10.1093/ecco-jcc/jjy222.096
S. Schreiber S. Ben-Horin J. Leszczyszyn R. Dudkowiak A. Lahat B. Gawdis-Wojnarska A. Pukitis M. Horynski K. Farkas J. Kierkus et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease Gastroenterology 2021 160 7 2340 2353 1:CAS:528:DC%2BB3MXhvFemtLzP 10.1053/j.gastro.2021.02.068 33676969
CT-P13 SC trial: unpublished data on file. 2023.
W.J. Sandborn B.G. Feagan P. Rutgeerts S. Hanauer J.F. Colombel B.E. Sands M. Lukas R.N. Fedorak S. Lee B. Bressler et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 2013 369 8 711 21 1:CAS:528:DC%2BC3sXhtlCrsrbO 10.1056/NEJMoa1215739 23964933
B.E. Sands W.J. Sandborn G. Van Assche M. Lukas J. Xu A. James B. Abhyankar K. Lasch Vedolizumab as induction and maintenance therapy for Crohn's disease in patients naïve to or who have failed tumor necrosis factor antagonist therapy Inflamm Bowel Dis 2017 23 1 97 106 10.1097/MIB.0000000000000979 27930408
B.E. Sands G. Van Assche D. Tudor G. Akhundova-Unadkat R.I. Curtis T. Tan Vedolizumab in combination with corticosteroids for induction therapy in Crohn's disease: a post hoc analysis of GEMINI 2 and 3 Inflamm Bowel Dis 2019 25 8 1375 1382 10.1093/ibd/izy384 30615117 6635819
R. Banerjee S.W. Chuah I.N. Hilmi D.C. Wu S.K. Yang D. Demuth D. Lindner S. Adsul Efficacy and safety of vedolizumab in Crohn's disease in patients from Asian countries in the GEMINI 2 study Intest Res 2021 19 1 83 94 10.5217/ir.2019.09160 33378612
B.E. Sands B.G. Feagan P. Rutgeerts J.F. Colombel W.J. Sandborn R. Sy G. D'Haens S. Ben-Horin J. Xu M. Rosario et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 2014 147 3 618 627.e3 1:CAS:528:DC%2BC2cXhsV2ltbnN 10.1053/j.gastro.2014.05.008 24859203
B.G. Feagan P. Rutgeerts B.E. Sands S. Hanauer J.F. Colombel W.J. Sandborn G. Van Assche J. Axler H.J. Kim S. Danese et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 2013 369 8 699 710 1:CAS:528:DC%2BC3sXhtlCrsrbN 10.1056/NEJMoa1215734 23964932
B.G. Feagan S. Schreiber D.C. Wolf J.L. Axler A. Kaviya A. James R.I. Curtis P. Geransar A. Stallmach R. Ehehalt et al. Sustained clinical remission with vedolizumab in patients with moderate-to-severe ulcerative colitis Inflamm Bowel Dis 2019 25 6 1028 1035 10.1093/ibd/izy323 30365009
B.G. Feagan D.T. Rubin S. Danese S. Vermeire B. Abhyankar S. Sankoh A. James M. Smyth Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists Clin Gastroenterol Hepatol 2017 15 2 229 239.e5 1:CAS:528:DC%2BC28XhslKnu7fP 10.1016/j.cgh.2016.08.044 27639327
E.V. Loftus Jr B.E. Sands J.F. Colombel I. Dotan J.M. Khalid D. Tudor P. Geransar Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1 Clin Exp Gastroenterol 2020 13 211 220 1:CAS:528:DC%2BB3cXisFamtbbF 10.2147/CEG.S248597 32606883 7295209
W.J. Sandborn J.F. Colombel R. Panaccione P.S. Dulai M. Rosario C. Cao M. Barocas K. Lasch Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis J Crohns Colitis 2019 13 2 172 181 10.1093/ecco-jcc/jjy149 30285104
B.E. Sands L. Peyrin-Biroulet E.V. Loftus Jr S. Danese J.F. Colombel M. Toruner L. Jonaitis B. Abhyankar J. Chen R. Rogers et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis N Engl J Med 2019 381 13 1215 1226 1:CAS:528:DC%2BC1MXhvFWnsbbO 10.1056/NEJMoa1905725 31553834
W.J. Sandborn F. Baert S. Danese Z. Krznaric T. Kobayashi X. Yao J. Chen M. Rosario S. Bhatia K. Kisfalvi et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis Gastroenterology 2020 158 3 562 572.e12 1:CAS:528:DC%2BC1MXit1GltL3I 10.1053/j.gastro.2019.08.027 31470005
S. Vermeire G. D'Haens F. Baert S. Danese T. Kobayashi E.V. Loftus S. Bhatia C. Agboton M. Rosario C. Chen et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: results from the VISIBLE 2 randomised trial J Crohns Colitis 2022 16 1 27 38 10.1093/ecco-jcc/jjab133 34402887
J.F. Colombel S.B. Hanauer W. Sandborn B.E. Sands S. Schreiber S. Danese J. Kierkus R. Kulynych M. Klopocka A. Lahat et al. DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: a phase 3, randomised, placebo-controlled study (LIBERTY-CD) J Crohn's Colitis 2023 17 1 i161 i162 10.1093/ecco-jcc/jjac190.0126
Sands BE, Hanauer SB, Colombel JF, Sandborn W, Schreiber S, Danese S, Klopocka M, Kulynych R, Kierkus J, Soltysiak A, et al. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: a phase 3, randomized, placebo-controlled study: results of the LIBERTY-UC study. J Crohn's Colitis. 2023;17(1):i623–4.
Entyvio: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf. Accessed: 4 Dec 2023.
CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active Crohn's disease (LIBERTY-CD). https://clinicaltrials.gov/ct2/show/NCT03945019. Accessed 4 Dec 2023.
CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active ulcerative colitis (LIBERTY-UC). https://clinicaltrials.gov/ct2/show/NCT04205643. Accessed 4 Dec 2023.
